| pubmed-article:2786697 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2786697 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:2786697 | lifeskim:mentions | umls-concept:C0003873 | lld:lifeskim |
| pubmed-article:2786697 | lifeskim:mentions | umls-concept:C0401925 | lld:lifeskim |
| pubmed-article:2786697 | lifeskim:mentions | umls-concept:C0021760 | lld:lifeskim |
| pubmed-article:2786697 | lifeskim:mentions | umls-concept:C0039097 | lld:lifeskim |
| pubmed-article:2786697 | lifeskim:mentions | umls-concept:C0004561 | lld:lifeskim |
| pubmed-article:2786697 | lifeskim:mentions | umls-concept:C0021027 | lld:lifeskim |
| pubmed-article:2786697 | lifeskim:mentions | umls-concept:C1521761 | lld:lifeskim |
| pubmed-article:2786697 | lifeskim:mentions | umls-concept:C0205263 | lld:lifeskim |
| pubmed-article:2786697 | pubmed:dateCreated | 1989-7-25 | lld:pubmed |
| pubmed-article:2786697 | pubmed:abstractText | First, IL-6 is produced by synovial tissue of patients with rheumatoid arthritis (RA) and is the principal mediator produced by that tissue inducing differentiation of B-lymphocytes into antibody-forming cells. The Leu-1+ subset of B-lymphocytes is induced by IL-6 to secrete rheumatoid factor (IgM with anti-Fc gamma specificity). Second, the main cell types producing IL-6 in cells dissociated from RA synovial tissue are mononuclear leukocytes. Connective tissue type cells (synoviocytes) cultured from RA synovial tissue produce IL-6 in response to IL-1 beta, and IL-6 formation is increased by TGF-beta. Glucocorticoids strongly inhibit and PGE2 slightly inhibits IL-1-induced IL-6 mRNA expression in synoviocytes. Production of IL-6 increases when undissociated RA synovial tissue is maintained in culture, thus suggesting release from inhibition by a factor or factors not yet identified. Third, the major known local effect of IL-6 in RA synovial tissue is the augmentation of antibody formation and the major known systemic effect is the induction of the synthesis by the liver of acute-phase proteins, especially C-reactive protein. Levels of circulating C-reactive protein are reported to decrease in RA patients receiving long-acting antirheumatic drugs, which would be consistent with the interpretation that immature monocyte-derived macrophages are major producers of IL-6 in these patients. | lld:pubmed |
| pubmed-article:2786697 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2786697 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2786697 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2786697 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2786697 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2786697 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2786697 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2786697 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2786697 | pubmed:issn | 0077-8923 | lld:pubmed |
| pubmed-article:2786697 | pubmed:author | pubmed-author:AllisonA CAC | lld:pubmed |
| pubmed-article:2786697 | pubmed:author | pubmed-author:LeeS WSW | lld:pubmed |
| pubmed-article:2786697 | pubmed:author | pubmed-author:NawataYY | lld:pubmed |
| pubmed-article:2786697 | pubmed:author | pubmed-author:EuguiE MEM | lld:pubmed |
| pubmed-article:2786697 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2786697 | pubmed:volume | 557 | lld:pubmed |
| pubmed-article:2786697 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2786697 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2786697 | pubmed:pagination | 230-8, discussion 239 | lld:pubmed |
| pubmed-article:2786697 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:2786697 | pubmed:meshHeading | pubmed-meshheading:2786697-... | lld:pubmed |
| pubmed-article:2786697 | pubmed:meshHeading | pubmed-meshheading:2786697-... | lld:pubmed |
| pubmed-article:2786697 | pubmed:meshHeading | pubmed-meshheading:2786697-... | lld:pubmed |
| pubmed-article:2786697 | pubmed:meshHeading | pubmed-meshheading:2786697-... | lld:pubmed |
| pubmed-article:2786697 | pubmed:meshHeading | pubmed-meshheading:2786697-... | lld:pubmed |
| pubmed-article:2786697 | pubmed:meshHeading | pubmed-meshheading:2786697-... | lld:pubmed |
| pubmed-article:2786697 | pubmed:meshHeading | pubmed-meshheading:2786697-... | lld:pubmed |
| pubmed-article:2786697 | pubmed:meshHeading | pubmed-meshheading:2786697-... | lld:pubmed |
| pubmed-article:2786697 | pubmed:meshHeading | pubmed-meshheading:2786697-... | lld:pubmed |
| pubmed-article:2786697 | pubmed:meshHeading | pubmed-meshheading:2786697-... | lld:pubmed |
| pubmed-article:2786697 | pubmed:year | 1989 | lld:pubmed |
| pubmed-article:2786697 | pubmed:articleTitle | IL-6 is the principal factor produced by synovia of patients with rheumatoid arthritis that induces B-lymphocytes to secrete immunoglobulins. | lld:pubmed |
| pubmed-article:2786697 | pubmed:affiliation | Department of Immunology and Cell Biology, Syntex Research, Palo Alto, California 94304. | lld:pubmed |
| pubmed-article:2786697 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2786697 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2786697 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2786697 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2786697 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2786697 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2786697 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2786697 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2786697 | lld:pubmed |
